Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight Blogs - ASH 2012: The combination of CHOP plus Rituxan (rituximab, Genentech/Roche; R-CHOP) has been the traditional standard of care in the United States and Europe for follicular lymphoma (FL) and mantle cell lymphoma (MCL). That regimen is associated with a range of adverse effects, including cardiac, hematologic, and neurologic toxicity, as well as infectious complications. Many physicians feel that CHOP has a role in treating more aggressive diseases such as diffuse large B-cell lymphoma, but debate as to whether such an aggressive regimen is warranted for treatment of patients with indolent lymphomas.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blogs from ASH 2012: Acute meloid leukemia (AML) is a disease of high unmet need with a generally poor prognosis. This is especially true in the elderly population, with only approximately 45% of these patients receiving aggressive therapy with curative intent (Kantar Health, CancerMPact Treatment Architecture, 2012). Dacogen (decitabine, Eisai /Astex) was recently approved in Europe for use in elderly AML patients (but was rejected by the FDA in the same indication), and Phase III trials of both sapacitabine (Cyclacel) and Vidaza (azacytidine, Celgene) are ongoing in newly diagnosed elderly AML patients.
    Continue Reading > | Go comment! | Share
  • New MOAs in Multiple Myeloma Shine at ASH 2012

    by Stephanie Hawthorne | Dec 10, 2012
    Stephanie Hawthorne
    Oncology Conference Insight Blog from ASH 2012: The multiple myeloma landscape is rapidly evolving, with the recent approval of Kyprolis (carfilzomib, Onyx) and the pending approval of pomalidomide (Celgene), both in the relapsed/refractory setting. We’ll see pivotal data for pomalidomide on Tuesday morning during ASH’s Late-Breaking Abstract session, but the first days of the conference have highlighted a few new mechanisms of action that are showing promising activity in multiple myeloma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog from SABCS 2012 Adjuvant therapy is improving outcomes in breast cancer and that can always be considered a positive result. Also, those patients who may be ineligible for aromatase inhibitors, will be able to benefit from the new 10-year tamoxifen standard of care. It is clear that long-term follow-up is the key for getting the most out of these adjuvant therapy studies.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog: SABCS 2012 With Afinitor recently approved in combination with hormone therapy and pursuing development in the adjuvant setting, and PD 0332991 now demonstrating highly meaningful clinical activity in ER+ patients, we are at the dawn of a new era in breast cancer that could have significant impact on the future course of the disease.
    Continue Reading > | Go comment! | Share